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Abstract  
Introduction: Although metabolic  syndrome (MetS)  is  evidently  associated  with  the  risk  of  
cardiovascular disease (CVD), recently its use has been questioned. We studied the utility of 
MetS diagnosis when estimating individual CVD risk.  
Methods: We compared 27 fertile women with MetS and 27 counterparts without the 
syndrome, matched pairwise according to well-known risk factors of CVD. Pulse wave 
velocity (PWV) and central blood pressure (cBP) were determined noninvasively via a 
SphygmoCor device. Arterial compliance was measured noninvasively with an 
HDI/PulseWaveTMCR-2000 arterial tonometer.  
Results: PWV (7.1 ± 2.5 vs. 6.5 ± 1.1 m/s, P = 0.037), and both systolic (120.9 ± 12.2 vs. 
111.5  ±  16.0  mmHg,  P  =  0.031)  and  diastolic  cBP  (81.3  ±  8.5  vs.  74.1  ±  11.2  mmHg,  P  =  
0.035) were higher in the MetS group. Systemic arterial compliance values were lower in both 
large (15.1 ± 8.0 vs. 16.1 ± 4.4 mL/mmHg×10, P = 0.034) and small arteries (7.1 ± 2.5 vs. 9.3 
± 3.2 mL/mmHg×100, P = 0.010) in women with MetS.  
Conclusions: Fertile women with MetS had increased arterial stiffness, as measured by three 
different  methods.  Our  results  highlight  the  utility  of  MetS  when  revealing  increased  
individual CVD risks in fertile-aged women. 
Keywords: arterial compliance, arterial stiffness, cardiovascular disease, central blood 
pressure, gestational diabetes mellitus, metabolic syndrome, pulse wave velocity 
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Key messages:  
x Women with MetS have increased arterial stiffness when measured by different 
methods.  
x MetS is a useful clinical tool to assess increased cardiovascular risk, particularly 
among fertile-aged women. 
 
 
Introduction  
Metabolic syndrome (MetS) is defined as a group of risk factors related to increased risks of 
cardiovascular diseases and diabetes (1). Although many diagnostic criteria have been 
proposed for MetS since the 1980s, hyperglycemia, dyslipidemia, hypertension, and 
abdominal obesity are recognized as key components (2). In recent decades the prevalence of 
MetS has increased significantly in parallel with the global epidemic of obesity (3). Although 
the  presence  of  MetS  is  associated  with  an  increased  risk  of  CVD (1,4,5),  the  results  of  the  
large INTERHEART study suggested that the use of dichotomous risk factors used in MetS 
classification may underestimate future CVD risk (6).  
Cardiovascular diseases (CVDs) are the leading causes of female mortality, responsible for 
one third of deaths in women globally (7,8). The appearance of CVD can differ between the 
sexes, making the identification of CVD in women challenging (9,10). Pregnancy can reveal a 
woman´s  tendency  to  be  at  an  increased  risk  of  health  problems  later  in  life.  Growing  
evidence suggests that women with a history of gestational diabetes mellitus (GDM) are at an 
increased risk of CVD, type 2 diabetes or MetS later in life (11-14). 
Arterial stiffness is an important marker of arteriosclerosis, predicting future CVD events (15-
18). With aging, the wall of the artery loses elasticity and becomes rigid (19-21). 
Measurement of carotid to femoral pulse wave velocity (PWV) as a marker of aortic stiffness 
has emerged as the gold standard method (18). There are also other ways to measure arterial 
stiffness noninvasively. Systemic arterial compliance can be determined by using radial artery 
pulse wave analysis (18,22). Central blood pressure (cBP) registered noninvasively seems to 
be more relevant than peripheral BP as regards the pathogenesis of CVD (23,24). It also 
correlates with cardiovascular risk in healthy people (25). 
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Weighing the possible value of MetS may be related to individual perspectives, i.e. the point 
of  view  of  an  epidemiologist  may  be  different  from  that  of  a  clinical  physician.  Hence,  the  
value of assessing MetS per se when estimating individual cardiovascular risk has been 
questioned (6,26-29). We aimed to study this by pairwise matching of fertile-aged women 
with  and  without  MetS,  in  relation  to  well-known risk  factors  of  CVD.  Our  special  interest  
was  to  determine  whether  or  not  there  are  differences  in  pulse  wave  velocity,  central  blood  
pressure and systemic arterial compliance between fertile-aged women with and without 
MetS. 
Material and methods 
Study population 
This cross-sectional study was performed at Kanta-Häme Central Hospital and Linnan 
Klinikka, Hämeenlinna, Finland. The complete study protocol has been described in detail 
previously (14). In brief, we investigated a total of 120 parturients from our area with a 
history of GDM during the index pregnancy and we compared them with 120 age-matched 
women with normal glucose metabolism during pregnancy. Index pregnancies and deliveries 
were 2–6 years before participating in the study. GDM was defined as a pathological value in 
a 75-g oral glucose tolerance test (OGTT) during pregnancy: venous plasma glucose  5.3 
mmol/L when fasting,  10.0 mmol/L at 1 hour or  8.6 mmol/L at 2 hours. The diagnostic 
criteria  of  GDM  were  the  same  as  in  current  Finnish  guidelines  (30).  MetS  was  defined  
according to the National Cholesterol Education Program (NCEP Adult Treatment Panel III), 
and  for  women  this  is  the  presence  of  at  least  three  of  the  following  five  criteria  (2):  waist  
circumference > 88 cm; serum triglycerides  1.7 mmol/L; serum high-density lipoprotein 
cholesterol (HDL-C) level < 1.3 mmol/L; blood pressure  130/85 mmHg; plasma glucose 
level  6.1 mmol/L or diabetes mellitus. 
We found 2.4-fold increased risk of MetS after previous GDM when compared with 
normoglycemic pregnancies (14). In the current analysis, we included all 27 women with 
MetS from a total of 240 participants in our original study. Every woman with MetS was 
compared with an individually paired counterpart without MetS. To avoid the confounding 
effects of well-known cardiovascular risk factors, the counterparts without MetS were 
matched according to age, previous GDM status, and serum concentrations of low-density 
lipoprotein cholesterol (LDL-C) and total cholesterol (TC) (Table 1). All the participants were 
of Caucasian origin. Both recruitment and examinations were carried out between January 
2013 and July 2014.  
We interviewed the participants as regards their medical histories and lifestyle habits. To 
analyze “yo-yo” dieting, we estimated total lifetime weight loss by adding together the 
kilograms lost during every previous intentional weight-loss period. Lifetime tobacco 
exposure was calculated as pack-years by multiplying years of smoking by the average 
number of packs smoked daily (31). One pack-year is defined as twenty cigarettes smoked 
every day for one year. 
Resting heart rate and brachial blood pressure of the participants was assessed automatically 
by using CR-2000 equipment (HDI/PulseWaveTMCR-2000, Hypertension Diagnostics, Inc., 
Eagan, Minnesota, USA) during the measurement of arterial compliance. The mean of three 
measurements  was  used  in  the  analysis.  Weight  (kg),  height  (cm)  and  waist  circumference  
(cm) were measured according to general recommendations. Waist circumference (WC) was 
measured midway between the lowest rib and the iliac crest. Body mass index (BMI) was 
calculated as weight in kilograms divided by height in meters squared (kg/m2). 
The study was conducted in accordance with the ethical principles outlined in the Declaration 
of Helsinki (32), and the protocol was approved by the Ethics Committee of Kanta-Häme 
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Hospital District (reference number 521/2010; date of approval 21.12.2010). Every 
participant was given both oral and written information on the study before she signed an 
informed consent document.  
Laboratory Methods 
Basic blood count and serum levels of creatinine, alanine transaminase (ALAT), fasting 
glucose and insulin, glycosylated hemoglobin (HbA1c), TC, HDL cholesterol, LDL 
cholesterol and triglycerides, and the urinary albumin to creatinine ratio, were analyzed 
according to validated methods as described in detail earlier after at least 12 hours of fasting 
(14,33). Serum concentrations of high-sensitivity C-reactive protein (hsCRP) were analyzed 
according to validated immunonephelometric (United Medix Laboratories Ltd., Espoo, 
Finland) and immunoturbidimetric (VITA Healthcare Services Ltd., Vita Laboratory, Helsinki, 
Finland) methods (34,35). Plasma concentrations of oxidized low-density lipoprotein 
(oxLDL) were determined by using a validated ELISA method (Mercodia AB, Uppsala, 
Sweden). The assay kits include the same monoclonal antibody (4E6) as originally described 
by Holvoet et al. (36,37).  
The homeostasis model assessment of insulin resistance (HOMA-IR) index is based on 
measurement of plasma glucose and insulin in a single sample and is commonly used as a 
parameter of the severity of insulin resistance (38). It was calculated in the following way: 
fasting insulin (mU/L) × fasting blood glucose (mmol/L)/22.5 (39). 
Determination of arterial stiffness and compliance  
Carotid–femoral PWV was measured by using the foot-to-foot velocity method from carotid 
and femoral waveforms, using a SphygmoCor device (AtCor Medical, Sydney, Australia). 
These were obtained transcutaneously at the right common carotid artery and the right 
femoral  artery,  with  the  subject  in  a  supine  position,  with  direct-contact  pulse  sensors.  The  
time  delay  (Dt  or  transit  time)  of  the  two  waveforms  was  registered,  and  the  distance  (D)  
between the carotid and femoral recording sites was obtained by subtracting the distance 
between the carotid measurement site to the sternal notch from the distance between the 
sternal notch and the femoral measurement site. PWV was calculated as follows: D/Dt (m/s) 
(18,25). PWV increases in stiff or less distensible arteries (23,25). Three measurements were 
performed to obtain average results for every participant. Only measurements that met the 
automatic quality-control cutoff were used in the final analysis.  
Central  BP  was  estimated  non-invasively  from  a  radial  artery  pulse  wave  (SphygmoCor  
device;  AtCor  Medical,  Sydney,  Australia),  which  involves  use  of  a  radial  pulse  and  a  
validated generalized transfer function to estimate central pressures from brachial BP and 
peripheral pulse waves (25). Three consecutive measurements were performed to obtain mean 
results for every participant. Values of cBP are indirect surrogate measures of arterial 
stiffness, but they provide additional information concerning pulse wave reflections (18).  
Radial artery pulse waves were measured non-invasively with an arterial tonometer 
(HDI/PulseWaveTMCR-2000, Hypertension Diagnostics, Inc., Eagan, Minnesota, USA), 
which involves use of a modified Windkessel pulse-contour method (40). This technique is 
based on an assumed model of the circulation which identifies reflections in diastole as a 
decaying sinusoidal wave (18,41). The equipment automatically records the proximal 
capacitive compliance of large arteries (C1), including the aorta, and the distal oscillatory 
compliance, which concerns endothelial function of the microvascular circulation or small 
arteries (C2) (18,41). During thirty seconds of measurement, values of C1 and C2 were 
automatically assessed as the mean of the five most similar pulse waves appearing. Three 
measurements were performed to obtain mean values for every participant. Arterial 
compliance  describes  the  ability  of  an  artery  to  expand  as  a  response  to  pulse  pressure.  
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Compliance can be understood as the inverse of stiffness – in a stiff artery compliance is low 
(42). 
Recordings of PWV, cBP, C1 and C2 were carried out in the morning after at least ten minutes 
of rest in a semi-sitting position. The participants were asked to refrain from eating, drinking 
caffeinated drinks, smoking and taking medication for 12 hours, and drinking alcohol for two 
days prior to measurement. All the measurements were performed by four experienced nurses. 
Statistical analysis 
Statistical analysis was carried out by using IBM® SPSS® Statistics Version 23 software 
(copyright 2015). Variables were tested for normality by way of Shapiro–Wilk tests. Data are 
presented as mean ± standard deviation (SD) if not mentioned otherwise. Differences in 
continuous variables between MetS participants and paired counterparts were studied by 
using paired t test  in cases of normality and by the Wilcoxon test  in cases of non-normality.  
Differences in binomial outcomes between the two paired study groups were tested by using 
McNemar’s test. The Hodges-Lehmann estimate was used for calculating the difference 
between MetS and their matched controls medians and 95% confidence interval (CI) for the 
difference. A two-tailed probability value of < 0.05 was considered significant. 
Results 
Variables of MetS defined according to NCEP Adult Treatment Panel III for women with 
MetS and their matched counterparts without MetS are shown in Table 2. There were no 
differences in family history of coronary heart disease, cerebrovascular disease or diabetes 
mellitus between the study groups (data not shown). In individual pairwise comparisons, no 
differences were found in diagnosed disorders or permanent medication for any chronic 
disease (data not shown). Further, there was no difference in current smoking in individual 
pairwise comparisons (6 vs. 4, P = 0.728). 
Baseline characteristics and laboratory findings in both groups are shown in Table 3. Body 
mass index was higher in the women with MetS, but their paired counterparts were also 
overweight (Table 3). Heart rate was 67.9 (± 8.8) beats per minute (bpm) in the MetS group 
and 65.7 (± 10.6) bpm among the paired controls (Difference = 2.2; 95% CI: -2.2, 6.6; P = 
0.211). There were no differences in the concentrations of white blood cells or platelets 
between the groups (data not shown), but that of hemoglobin was higher among women with 
MetS (Table 3). The concentration of HbA1c was 34.6 (± 2.9) mU/L in the MetS group, and 
34.7 (± 2.5) mU/L in the paired controls (Difference = -0.1; 95% CI: -1.7, 1.4; P = 1.000). The 
urinary albumin to creatinine ratio was significantly higher among women with MetS, 0.7 (± 
0.4) mg/mmol vs. 0.5 (± 0.3) mg/mmol, Difference = 0.2; 95% CI: 0.0, 0.4 (P = 0.034), 
respectively. 
As measured by three different methods, arterial stiffness values differed significantly 
between the fertile women with MetS and their matched counterparts without the syndrome. 
Arterial stiffness was higher among the women with MetS than in their matched counterparts 
when measured by means of PWV (Figure 1), as were both systolic and diastolic cBP (Figure 
2). Values of systemic arterial compliance (both C1 and C2) were significantly lower in the 
MetS group (Figure 3). 
Discussion  
Women with MetS had higher PWV values when compared with paired women without the 
syndrome, suggesting that MetS in fertile-aged women is associated with increased arterial 
stiffness.  Further,  women  with  MetS  had  increased  cBP,  as  well  as  decreased  C1  and  C2  
values when compared with their counterparts without MetS, thus providing further support 
for the finding. 
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Increased PWV, as a measure of arterial stiffening, is a strong predictor of cardiovascular 
events and mortality (43). As reviewed by Vlachopoulos et al., an increase in PWV of 1 m/s is 
related to a 14–15% increase in cardiovascular events, cardiovascular mortality and all-cause 
mortality (43). There are several plausible reasons for the current finding of increased PWV in 
women  with  MetS.  Small  dense  LDL  (sdLDL),  i.e. poor  quality  of  LDL,  known  to  be  
associated with MetS and hypertriglyceridemia has found to be an important predictor of 
atherosclerosis (44,45). Like sdLDL, also circulating triglyceride rich lipoproteins may induce 
endothelial dysfunction (46,47). Chronic hyperglycemia and hyperinsulinemia promote the 
development of arterial wall hypertrophy by increasing local activity of the renin-angiotensin-
aldosterone system (48). Moreover, high blood pressure stimulates excessive collagen 
production in the arterial wall (48) and insulin resistance promotes the formation of advanced 
glycation end-products and collagen cross-linking (49). Furthermore, decreased vasodilatory 
effects of insulin and free fatty acids cause impaired endothelial function (48). MetS can also 
be considered to be a pro-inflammatory state, which could cause endothelial dysfunction (50). 
All these changes in arterial wall structure and function have adverse effects on the 
cushioning capabilities of arteries, thus increasing arterial stiffness. 
Carotid–femoral PWV is widely studied and considered as a gold standard in the evaluation 
of arterial stiffness (17). Arterial stiffness can also be determined by measuring cBP (17) or 
compliance of large (C1) and small (C2) arteries (40). As discussed in a consensus document 
by Agabiti-Rosei et al. (25), increased cBP has been shown to correlate with cardiovascular 
risk in apparently healthy subjects and in patients with atherosclerotic disease. Moreover, 
decreased values of C1 and C2 have been found to be associated with MetS (51) and 
increased cardiovascular risk as estimated by using FINRISK and SCORE risk models (52). 
We found higher cBP, and lower C1 and C2 values among fertile-aged women with MetS 
when compared with women without the syndrome. This provides further evidence of the 
negative effects of MetS on arterial stiffness among fertile-aged women. Between the study 
groups there was a small but significant difference in microalbuminuria. As a marker of 
endothelial dysfunction, this finding also highlights the effect of MetS on arterial stiffness. 
The number of subjects was relatively small, but the number of patients was big enough to 
show the statistically significant difference between the matched groups. Hence, the 
confounding factors were used as matching criteria. In this setting, according to all methods 
used women with MetS had increased arterial stiffness. 
Physical activity is known to be crucial in the prevention of CVD. Two recent studies are part 
of a continuum concerning research into atherosclerotic risk factors among men with MetS 
and physically active (PhA) men (53,54). Pohjantähti-Maaroos et al. found that PhA men had 
better C1 values compared with MetS participants, but no difference was found as regards C2 
(54). Higher numbers of smokers and greater alcohol intake were more often present among 
men with MetS compared with PhA subjects (54). Our study has expanded research into MetS 
in women. In contrast to earlier findings, there were no significant differences in pack-years 
of smoking or alcohol intake between the paired study groups. The apparent discrepancy of 
these results may be attributed to variability in selection of controls. In agreement with this, 
MetS per se seems to be an independent predictor of increased arterial stiffness in the present 
study. 
Initially successful weight losses followed by weight regain (weight cycling or so called “yo-
yo” dieting) is associated with body-weight excess and abdominal fat accumulation (55). 
Nonalcoholic fatty liver disease is commonly associated with obesity, insulin resistance, 
dyslipidemia and type 2 diabetes, and can thus be regarded as the hepatic manifestation of 
metabolic syndrome (56). We found no difference in lifetime weight loss between the paired 
study groups. The women in both groups were overweight. In contrast, both BMI and serum 
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concentrations of ALAT were higher among women with MetS compared with women 
without the syndrome, reflecting the hepatic manifestation of MetS.  
Diagnosis of MetS has been the subject of severe criticism, and it has even been suggested 
that MetS “should rest in peace” (57,58). The major concerns are the uncertain 
pathophysiology of the syndrome, the use of discrete thresholds to define abnormalities, the 
existence of different definitions, the exclusion of other important cardiovascular risk factors 
(e.g. age, sex, family history, LDL-cholesterol), and the lack of specific treatment for the 
syndrome (57,58). However, MetS has previously been shown to be associated with an 
increased risk of CVD (1,3,4,59), and the risk of CVD associated with MetS is even greater 
than the risk associated with the individual components (5). Moreover, it has been suggested 
that MetS could be a valuable public-health tool as it can be used to identify high-risk 
individuals at a young age (60). Our results, showing increased arterial stiffness in fertile-aged 
women with MetS support the use of MetS in the evaluation of CVD risk. 
In conclusion, fertile-aged women with MetS have increased arterial stiffness as measured by 
three different methods, even when their counterpart are matched according to many other 
well-known CVD risk factors. The present results strongly support the clinical use of MetS as 
a tool for cardiovascular risk assessment, particularly among fertile-aged women. 
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Figure legends 
Figure 1 PWV in the MetS women and their matched controls without the syndrome.  
Median (minimum, maximum) PWV among matched control women was 6.3 (5.1, 9.7) m/s, 
and among women with MetS, 6.9 (5.9, 9.2) m/s (Difference = -0.7; 95% CI: -1.1, -0.0; P = 
0.037).  
Figure  2 Central  systolic  (A)  and  diastolic  pressures  (B)  in  the  MetS  women  and  their  
matched controls without the syndrome.  
A: Median (minimum, maximum) central systolic pressure among matched control women 
was 107 (90, 154) mmHg and among women with MetS, 120 (97, 147) mmHg (Difference = -
12.5; 95% CI: -20.3, -1.2; P = 0.031). 
B: Median (minimum, maximum) central diastolic pressure among matched control women 
was 73 (56, 106) mmHg and among women with MetS, 81 (65, 94) mmHg (Difference = -9.3; 
95% CI: -15.3, -0.7; P = 0.035).   
Figure  3 Large-  (A)  and  small-artery  (B)  compliance  index  values  in  the  MetS  women and  
their matched controls without the syndrome. 
A: The median (minimum, maximum) large-artery compliance index value among matched 
control women was 15.5 (7.2, 25.7) mL/mmHg×10 and among women with MetS, 13.8 (8.8, 
53.3) mL/mmHg×10 (Difference = 2.0; 95% CI: 0.4, 4.2; P = 0.034). 
B: The median (minimum, maximum) small-artery compliance index value among matched 
control women was 9.4 (3.5, 15.3) mL/mmHg×100 and among women with MetS, 7.8 (1.8, 
9.7) mL/mmHg×100 (Difference = 2.2; 95% CI: 0.7, 3.5; P = 0.010).  
Table legends 
Table 1 Parameters matched among MetS participants and their counterparts without MetS. 
Table  2 Variables  of  MetS  in  the  MetS  women  and  their  matched  controls  without  the  
syndrome. 
Table 3 Baseline characteristics and laboratory findings in the MetS women and their 
matched controls without the syndrome. 
Table 1. Parameters matched among MetS participants and their counterparts without MetS.  
Matching parameter MetS 
(n = 27) 
Control 
(n = 27) 
   P value 
 Mean SD Mean SD Difference 95% CI  
Age, years 36.8 4.7 36.6  4.5 0.2 -2.3, 2.7 0.880 
Previous GDM, n (%) 19  70 19 70   1.000 
TC, mmol/L 5.1  1.2 5.2 0.9 -0.1 -0.7, 0.5 0.851 
LDL-C, mmol/L 3.4  0.9 3.3 0.8 0.1 -0.4, 0.5 0.768 
CI: confidence interval; GDM: gestational diabetes mellitus; LDL-C: low-density lipoprotein 
cholesterol; MetS: metabolic syndrome; TC: total cholesterol 
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Table 2. Components of MetS in the MetS women and their matched controls without the 
syndrome.  
Determinant of MetS MetS 
(n = 27) 
Control 
(n = 27) 
   P value 
 Mean SD Mean SD Difference 95% CI  
Waist circumference, cm 107.7 11.0 97.8 14.1 9.9 2.6, 17.2 0.010 
Systolic BP, mmHg 135.7 13.6 125.9 18.7 9.8 0.2, 19.4 0.021 
Diastolic BP, mmHg 78.4 8.1 73.0 12.1 5.4 -0.6 11.4 0.053 
Fasting glucose, mmol/L 5.7 0.6 5.4 0.4 0.3 0.0, 0.6 0.029 
T2DM, n (%) 1* 4 0 0   1.000 
TG, mmol/L 1.7 0.9 1.0 0.3 0.7 0.4, 1.1 < 0.001 
HDL-C, mmol/L 1.2 0.2 1.6 0.2 -0.3 -0.5, -0.2 < 0.001 
BP: blood pressure; CI: confidence interval; GDM: gestational diabetes mellitus; HDL-C: high-density 
lipoprotein cholesterol; TG: triglycerides; T2DM: type 2 diabetes mellitus  
* T2DM in a woman with previous GDM 
 
Table 3. Baseline characteristics and laboratory findings in the MetS women and their 
matched controls without the syndrome.  
 
MetS 
n = 27 
Control 
n = 27 
  P value 
 
Mean SD Mean SD Difference 95% CI  
Pack-years of 
smoking 
4.1 8.7 1.9 4.8 2.1 -1.8, 6.0 0.276 
Alcohol intake, 
g/day 
1.1  1.4 1.5 1.6 -0.6 -1.4, 0.1 0.242 
Lifetime weight 
loss, kg 
30.4 31.4 28.0 35.2 2.4 -18.7, 23.6 0.657 
BMI, kg/m2 33.5  6.2 28.9 5.0 4.6 1.2, 7.9 0.010 
Clinical chemistry        
  Hemoglobin, g/L 138.2 6.9 130.5 9.1 7.2 2.5, 11.9 0.004 
  hsCRP, mg/L 3.6 4.1 3.7 5.2 -0.1 -2.7, 2.6 0.516 
  oxLDL, U/L 48.3 14.6 48.0 17.1 0.3 -8.1, 8.7 0.942 
  F-insu, mU/L 9.0 5.9 6.4 4.3 2.6 -0.5, 5.7 0.073 
  ALAT, U/L 32.3 24.1 22.2 20.5 10.3 0.6, 19.5 0.022 
  Crea, µmol/L 65.3 9.0 64.6 5.4 0.7 -3.8, 5.2 0.748 
HOMA-IR 2.3  1.5 1.6 1.1 0.7 -0.1, 1.5 0.046 
ALAT: alanine transaminase; BMI: body mass index; CI: confidence interval; Crea: creatinine; F-insu: 
fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; hsCRP: high-
sensitivity C-reactive protein; MetS: metabolic syndrome; oxLDL: oxidized low-density lipoprotein 
(plasma concentration) 
 
